FindTrial
Sign In

Impact of CYP2C19 genotype and individual antipletelet teratment on clinical outcomes of patients post PCI

Individual antipletelet teratment according to post-treatment pletelet reactivity and CYP2C19 genotype on patients post PCI

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INC-17011550
Enrollment
Unknown
Registered
2017-06-02
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

concrol group:clopidogrel75mg,qd
individual treatment group:clopidogrel

Sponsors

Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Receive PCI treatment during this study

Exclusion criteria

Exclusion criteria: 1. Not agree to enter this study; 2. Have contraindications for the use of aspirin, clopidogrel or ticagrelor; 3. Can not receive medicine treatment according to this protocol

Design outcomes

Primary

MeasureTime frame
MACE;—

Countries

China

Contacts

Public ContactMei Gao

The Fifth People's Hospital of Jinan City

gaomei0217@163.com+86 13791126569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026